BMS-754807

For research use only. Not for use in humans.

目录号:S1124

BMS-754807 Chemical Structure

CAS No. 1001350-96-4

BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂,在无细胞试验中IC50为1.8 nM/1.7 nM,对Met,Aurora A/B,TrkA/B和Ron作用稍弱,对Flt3, Lck,MK2,PKA,PKC等几乎没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1480.09 现货
RMB 2214.12 现货
RMB 6299.66 现货
RMB 16953.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的BMS-754807发表文献27篇:

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂,在无细胞试验中IC50为1.8 nM/1.7 nM,对Met,Aurora A/B,TrkA/B和Ron作用稍弱,对Flt3, Lck,MK2,PKA,PKC等几乎没有抑制活性。Phase 2。
特性 胰岛素样生长因子-1R/IR家族激酶的多重抑制剂
靶点
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
体外研究

BMS-754807 有效抑制人类多种不同组织来源的肿瘤细胞系的生长,包括间充质(尤文氏肉瘤,横纹肌肉瘤,神经母细胞瘤,和脂肪肉瘤),上皮(乳腺,肺,胰腺,结肠,和胃),和造血(多发性骨髓瘤和白血病)组织,IC50值从5 nM 到 365 nM。BMS-754807 抑制 IGF-1R-Sal 细胞和 RH41细胞增殖,IC50分别为7 nM 和5 nM。BMS-754807作用于IGF-1R-Sal, Rh41 和 Geo细胞,抑制IGF-1R磷酸化,IC50分别为13 nM, 6 nM 和 21 nM。BMS-754807作用于 IGF-1R-Sal, Rh41 和Geo细胞,抑制Akt磷酸化,IC50 分别为22 nM, 13 nM 和 16 nM。BMS-754807诱导Rh41细胞凋亡。[1] BMS-754807作用于IGF-Sal 细胞系,抑制IGF-1R (IC50 = 13nM) 和下游靶点Akt (IC50 = 22nM) 和MAPK(IC50 = 13nM) 的磷酸化。[2] 在儿科临床前期试验计划(PPTP)中,BMS-754807作用于23种细胞系,平均EC50值为0.62 µM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal NF\uNYhMcW6jc3WgZZN{[Xl? MXzpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR|UxKD1iMUPuUUk> MoLVNVk4PzhyMkS=
IGF-Sal Mo\zS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NG\Nd|dKSzVyPUegcm0> NV\CR5pvOTl5N{iwNlQ>
CCRF-CEM (ALL) NYHrV3hWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYf+OUDPxE1? M2DZemROW09? Mk\oTWM2OD1zLkKzPUDPxE1? NXy5Z29GOTl7OU[yO|I>
PC3 MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX3+OUDPxE1? M37GfGROW09? NUXKUYJtUUN3ME2wMlk3PSEQvF2= NGfySVIyQTl7NkK3Ni=>
JD MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3\ucp42KM7:TR?= NUXWenM3TE2VTx?= NV7Hb4h6UUN3ME2wMlM6OSEQvF2= M1m2O|E6QTl4Mkey
DU145 M{fTc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn7oglUh|ryP NEDIdm9FVVOR NGLqd4pKSzVyPUGuOFY2KM7:TR?= NGGxfncyQTl7NkK3Ni=>
KAG MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHTXV2p,PSEQvF2= NFPRdItFVVOR MlXxTWM2OD1zLk[2OUDPxE1? NIHPRnUyQTl7NkK3Ni=>
K-562 (CML) NFzueoVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnnlglUh|ryP NVnve3BJTE2VTx?= NVTHbXNVUUN3ME2yMlMxOiEQvF2= NIfSXIgyQTl7NkK3Ni=>
B6-P210 (Murine ALL) NIfCZmJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1r1Z542KM7:TR?= NXryTHhGTE2VTx?= MlTzTWM2OD1zLkK5N{DPxE1? NUHvcGRnOTl7OU[yO|I>
LN CAP-FGC MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Ml\tglUh|ryP MUfEUXNQ NXHLZmQzUUN3ME2xMlQ{PCEQvF2= NILYcnMyQTl7NkK3Ni=>
VW NFvFVXZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Ml\PglUh|ryP MYrEUXNQ M2PPTmlEPTB;MD6wNVkh|ryP M3;zblE6QTl4Mkey
MV411 (B Myelomonocytic) MnjWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NE\SVXB,PSEQvF2= NI\3PW5FVVOR NU\ROJpXUUN3ME2wMlM{KM7:TR?= MmjaNVk6QTZ{N{K=
MDA-PCa-2b NX;vUFlxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1v5T542KM7:TR?= M2ftNGROW09? MnHsTWM2OD1yLkC5PEDPxE1? MmKxNVk6QTZ{N{K=
LG MoD5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGTRfYd,PSEQvF2= MXXEUXNQ NVm3VlhEUUN3ME2wMlA{QCEQvF2= M3vDTlE6QTl4Mkey
RS411 (B cell precursor-ALL) M4nhPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVPzXmxQhjVizszN NXO3eYk4TE2VTx?= MoHETWM2OD1yLkGwNkDPxE1? M1e2VFE6QTl4Mkey
22-r-1 M4\QcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mo\CglUh|ryP M3;idmROW09? NHT5[JFKSzVyPUCuNVc2KM7:TR?= NIj5dY0yQTl7NkK3Ni=>
5838 MkGyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXf+OUDPxE1? NVyxbI5jTE2VTx?= MlLwTWM2OD1yLkCzOEDPxE1? MmDQNVk6QTZ{N{K=
P388 (Murine) NIHsO5pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mlz4glUh|ryP MWrEUXNQ MmThTWM2OD12LkK3JO69VQ>? M3K4PFE6QTl4Mkey
A2780/S MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYj+OUDPxE1? MYnEUXNQ MUXJR|UxRTBwMUKyJO69VQ>? Moi0NVk6QTZ{N{K=
RDES M2rEXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2rDOJ42KM7:TR?= NV;VXIh[TE2VTx?= NVPsPJpCUUN3ME2wMlAyOiEQvF2= MYWxPVk6PjJ5Mh?=
B6-T315I (Murine B-ALL) NIq2VnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUT+OUDPxE1? NVTVNmJMTE2VTx?= MoW0TWM2OD1{LkizJO69VQ>? MnnzNVk6QTZ{N{K=
TOV 112D NEHrO4ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlfQglUh|ryP MnLvSG1UVw>? MXvJR|UxRTJwMUS2JO69VQ>? M2\yd|E6QTl4Mkey
TC32 M1rCV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1LFdZ42KM7:TR?= MXTEUXNQ MoPsTWM2OD1yLkCwPEDPxE1? M4LNdlE6QTl4Mkey
HL60 (acute myelocytic) MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoPuglUh|ryP NE\sRVZFVVOR NFfNfWRKSzVyPUCuNVIh|ryP Mnn5NVk6QTZ{N{K=
TOV 21G NEPRTlVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnXtglUh|ryP MYDEUXNQ NFfNfpBKSzVyPUSuNlc6KM7:TR?= Mom0NVk6QTZ{N{K=
TC71 MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1jhbZ42KM7:TR?= M3O3NGROW09? NXjmbXdmUUN3ME2wMlAyPCEQvF2= NELHPG0yQTl7NkK3Ni=>
HPN-ALL (T-cell) NWS0UFdqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmLkglUh|ryP MoXPSG1UVw>? MUTJR|UxRTBwNUKg{txO MVGxPVk6PjJ5Mh?=
A2780R MlHyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYXKW2xlhjVizszN Mln0SG1UVw>? MWHJR|UxRTFwNU[0JO69VQ>? NVuwVGdGOTl7OU[yO|I>
Rh1 Mn[zS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFn2SVl,PSEQvF2= NEHPTmZFVVOR MlX3TWM2OD1yLkCyO{DPxE1? MXexPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid) M1P6NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYTqXmRRhjVizszN NIDjbmxFVVOR NFnxfllKSzVyPUCuNVYh|ryP NVLOTFBwOTl7OU[yO|I>
sk-ov-3 Ml7pS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX;+OUDPxE1? MlW3SG1UVw>? MonETWM2OD13LkGg{txO MmXUNVk6QTZ{N{K=
ME M2HHSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXLETlNlhjVizszN M3HTS2ROW09? M4jOfWlEPTB;MD6wNVUh|ryP NYHDPW1sOTl7OU[yO|I>
L1210 (Murine lymphocytic) M4\JeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1r3UJ42KM7:TR?= NH7BUpZFVVOR M3PCO2lEPTB;Mj6zPUDPxE1? NFHPUVgyQTl7NkK3Ni=>
sw-626 NEnz[m9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlfLglUh|ryP MX\EUXNQ M2\6UWlEPTB;Mj6zNFYh|ryP NYfkV2hVOTl7OU[yO|I>
CTR NGnvbItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYP+OUDPxE1? M4O2NmROW09? M1:wXWlEPTB;MD6yOVMh|ryP M{C3OVE6QTl4Mkey
ML2 (Myelomonocytic) M1LNemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoD6glUh|ryP NEfuV41FVVOR NIfTfnlKSzVyPUCuNFkh|ryP MofwNVk6QTZ{N{K=
ovcar-3 MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX\U[IRKhjVizszN Mn;iSG1UVw>? M2XIdmlEPTB;NTFOwG0> MmDGNVk6QTZ{N{K=
Rh36 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIHqUnp,PSEQvF2= NFjKNYdFVVOR MlzITWM2OD1zLkSzNkDPxE1? MljTNVk6QTZ{N{K=
MOLM-13 (acute myeloid) MnnoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHi4N|F,PSEQvF2= NYXEb2Y5TE2VTx?= NEnRfJBKSzVyPUCuOFIh|ryP NFXFe5UyQTl7NkK3Ni=>
ovcar-4 NGDzZYVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWL+OUDPxE1? M36xdmROW09? MnrBTWM2OD1zIN88US=> MlrpNVk6QTZ{N{K=
Rh41 NX7tRWpyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1\6R542KM7:TR?= Ml\hSG1UVw>? MYfJR|UxRTBwMEC1JO69VQ>? NWPJWWhlOTl7OU[yO|I>
Mutz 2 (acute myeloid) NYDEcZhiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXv+OUDPxE1? MV;EUXNQ NH2yWo5KSzVyPUGuNVUh|ryP M2O0O|E6QTl4Mkey
ovcar-5 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoTqglUh|ryP NYfkcFVpTE2VTx?= NH\mbGlKSzVyPUCuNFUh|ryP Mnj5NVk6QTZ{N{K=
RD1 Mo\3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUTkdlJzhjVizszN MXXEUXNQ MVzJR|UxRTBwME[4JO69VQ>? M2DBXVE6QTl4Mkey
OCI-AML 2 (acute myeloid) MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2nWRZ42KM7:TR?= NVvCVVhQTE2VTx?= MnTnTWM2OD1|LkOzJO69VQ>? MoLuNVk6QTZ{N{K=
786-O MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVjHeXg6hjVizszN NF\SOVBFVVOR MoO2TWM2OD1zLk[0O{DPxE1? NIPHSJkyQTl7NkK3Ni=>
A673 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{PXWZ42KM7:TR?= MmDxSG1UVw>? MlPDTWM2OD1yLkSwPEDPxE1? NYDDUZJGOTl7OU[yO|I>
TALL-1 (T-cell) NXLnOW1NT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEPp[XB,PSEQvF2= NWL3cWZzTE2VTx?= NIP6c5JKSzVyPUGuNlgh|ryP MmezNVk6QTZ{N{K=
151-B MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn;WglUh|ryP MUnEUXNQ NIHtUFhKSzVyPUKuOlch|ryP MXqxPVk6PjJ5Mh?=
PFSK-1 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVf+OUDPxE1? M37SbGROW09? M2jkcmlEPTB;MD6xN|Ih|ryP NHvJfmQyQTl7NkK3Ni=>
THP-1 M1;aeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3;XZp42KM7:TR?= NYXDPXpiTE2VTx?= NFqzcoNKSzVyPU[uOVgh|ryP MXixPVk6PjJ5Mh?=
HEK293 NX35U|JmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M33kT542KM7:TR?= MlHLSG1UVw>? MXHJR|UxRTBwOUG1JO69VQ>? MnS3NVk6QTZ{N{K=
DAOY MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlPNglUh|ryP NWrRZppbTE2VTx?= MnOzTWM2OD1zLkm3PUDPxE1? NWe2WIc1OTl7OU[yO|I>
SET2 M2WxNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYTHfZBJhjVizszN NF;UfFNFVVOR MYDJR|UxRTBwMkm4JO69VQ>? MnTDNVk6QTZ{N{K=
HTB-46 MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MY\+OUDPxE1? NEHUXXRFVVOR MkG0TWM2OD13LkK1JO69VQ>? NWnRWm02OTl7OU[yO|I>
SK-NAS MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NY[5fpZ3hjVizszN NHfCVVhFVVOR MnW0TWM2OD1yLkS5O{DPxE1? NH3aWFAyQTl7NkK3Ni=>
CTLL2 NG\WTXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVT+OUDPxE1? NWPjTmZXTE2VTx?= MVXJR|UxRjFwMECg{txO NVH5bXl4OTl7OU[yO|I>
HTB-47 M4XnW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXr+OUDPxE1? M{[3PWROW09? M2LVXGlEPTB;Mj6wOVYh|ryP NUXac2ZNOTl7OU[yO|I>
LAN-1 MoTPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFL0dJF,PSEQvF2= NUjDcIlbTE2VTx?= M4naWWlEPTB;MD6wOEDPxE1? MnzINVk6QTZ{N{K=
ST486 NYrQepVCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUT+OUDPxE1? MUHEUXNQ NEfBN3pKSzVyPUGuNVkh|ryP NFG4[VQyQTl7NkK3Ni=>
HS766T NEfnUYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUfvOYVyhjVizszN NEHuSVdFVVOR M3zvfmlEPTB;Mj6wNFEh|ryP NYrBWmxJOTl7OU[yO|I>
IMR-32 NYn0PWZMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXj+OUDPxE1? NWfZcXFDTE2VTx?= NGHMVIdKSzVyPUCuNlYyKM7:TR?= MkO5NVk6QTZ{N{K=
Daudi (Burkitt's) M4Xad2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{n1VZ42KM7:TR?= NFe5UIpFVVOR MU\JR|UxRTJwNkO3JO69VQ>? NX3URZdQOTl7OU[yO|I>
Aspc-1 MoLBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIXvTll,PSEQvF2= M4\tZWROW09? MYfJR|UxRTBwM{e5JO69VQ>? NYniOVZoOTl7OU[yO|I>
SK-NSH MmTtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYL+OUDPxE1? NHHsSJZFVVOR M{G4OmlEPTB;MD6xN|kh|ryP NH\3V|QyQTl7NkK3Ni=>
MEC-1 (Chronic B cell) NV7HRXR3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH:yb|F,PSEQvF2= NWXESlVLTE2VTx?= MYrJR|UxRTJwNkO3JO69VQ>? NFvibFEyQTl7NkK3Ni=>
Capan-2 NVHtNIE5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH;qXIF,PSEQvF2= NE\6RnVFVVOR NILWWJZKSzVyPUGuO|c1KM7:TR?= MknuNVk6QTZ{N{K=
SHSY5Y MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVjQSYpnhjVizszN MoT4SG1UVw>? Mn70TWM2OD1yLkGwOkDPxE1? MnvUNVk6QTZ{N{K=
U937 (Histioocytic) NIPQNJBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVP+OUDPxE1? NH33fmRFVVOR MULJR|UxRjVwMECg{txO NXT5dYc2OTl7OU[yO|I>
Bxpc-1 NHf6SldIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVOwbJpShjVizszN NGrDNYZFVVOR M1XTWWlEPTB;MT65NlQh|ryP NF7XdJcyQTl7NkK3Ni=>
Bxpc-3 NF\iUFdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmfqglUh|ryP NFrObYJFVVOR M3q4[2lEPTB-NT6wNEDPxE1? MnjzNVk6QTZ{N{K=
HTB-92 M2Xqb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlvKglUh|ryP MXXEUXNQ M4TtO2lEPTB;MT6wNkDPxE1? NIrmb3EyQTl7NkK3Ni=>
OCI-LY10 (B-cell) NWjOTHd3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX\+OUDPxE1? NUPYZmV7TE2VTx?= NWrtWoF1UUN3ME2wMlQ2KM7:TR?= M4PaSFE6QTl4Mkey
PANC-1 MoTxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2LBN542KM7:TR?= NFXoWIZFVVOR NU\NVotyUUN3ME61MlAxKM7:TR?= NHXGO20yQTl7NkK3Ni=>
To184.T M1XEV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWfUZYVwhjVizszN NWPQXI1ZTE2VTx?= MYjJR|UxRTBwNE[5JO69VQ>? MYmxPVk6PjJ5Mh?=
OCI-LY19 (B-cell) NYK0SnFHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Ml;HglUh|ryP NH;T[ZhFVVOR MkLpTWM2OD1yLkSg{txO NG\zd2oyQTl7NkK3Ni=>
PANC-1 BM NGS3SIVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXj+OUDPxE1? MUDEUXNQ MoLCTWM2OD53LkCwJO69VQ>? NVO2dm4xOTl7OU[yO|I>
SA-4 M37Idmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWL+OUDPxE1? MmHUSG1UVw>? M3XhXmlEPTB;MT6zNFEh|ryP NIOwPVQyQTl7NkK3Ni=>
RPMI 8226 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUOzeJFXhjVizszN MW\EUXNQ MVPJR|UxRTFwMkmzJO69VQ>? MlO4NVk6QTZ{N{K=
HPAF-II NXjuS|d6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYn+OUDPxE1? M1HhOWROW09? NFnEPYhKSzVyPUCuOlQ1KM7:TR?= MkjONVk6QTZ{N{K=
SHP-77 NHrrVolIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWm4[3JthjVizszN MnHXSG1UVw>? NHzZbG1KSzVyPUGuPFg5KM7:TR?= MoPwNVk6QTZ{N{K=
U266 B1 NV7G[WV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFPSOFB,PSEQvF2= NVvnWG9MTE2VTx?= M{LwdmlEPTB;MT62Olkh|ryP M4\vSlE6QTl4Mkey
Hs700t NHHkcGhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnvJglUh|ryP Mn;ZSG1UVw>? M4jhXWlEPTB;MD6yN|Eh|ryP NEfWZnAyQTl7NkK3Ni=>
NCI-446 Mn\vS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX7hdZVMhjVizszN NFztfHFFVVOR NXXIdYpHUUN3ME2xMlE2PCEQvF2= NGnFUGYyQTl7NkK3Ni=>
H929 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWH+OUDPxE1? MXXEUXNQ M2TXWGlEPTB;MD6wNVQh|ryP M3;6flE6QTl4Mkey
PL45 MlPFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmHvglUh|ryP NUPuboRNTE2VTx?= MlfRTWM2OD1{LkK1OUDPxE1? MkLxNVk6QTZ{N{K=
NCI-H383 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnriglUh|ryP NXfPTItjTE2VTx?= NVrUSFlWUUN3ME61MlAxKM7:TR?= MWOxPVk6PjJ5Mh?=
JJN3 NGnwTpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVr+OUDPxE1? MYjEUXNQ NFHrXpVKSzVyPUKuOFM{KM7:TR?= NX;MRVFnOTl7OU[yO|I>
SU.86.86 MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVP+OUDPxE1? MmfTSG1UVw>? MlHaTWM2OD1{Lk[3NkDPxE1? M3;6RlE6QTl4Mkey
H1299 NXL0PWEyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnG2glUh|ryP MlTzSG1UVw>? MWnJR|UxRjVwMECg{txO MmDqNVk6QTZ{N{K=
MDA-MB-468 NXvDOVlWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXTkO2hQhjVizszN M361eWROW09? M{iweWlEPTB;MD61NFQh|ryP M3j6VFE6QTl4Mkey
SW1990 Ml\FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV3+OUDPxE1? NV:5NosyTE2VTx?= NHvHUWJKSzVyPUCuPFI3KM7:TR?= Mo[zNVk6QTZ{N{K=
Calu-6 NFW5RmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX7+OUDPxE1? M3HVemROW09? MkDGTWM2OD53LkCwJO69VQ>? NEGxOIIyQTl7NkK3Ni=>
MDA-MB-231 NV3PblZ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MmjMglUh|ryP MoX5SG1UVw>? NE\MR3BKSzVyPUGuOlQ5KM7:TR?= MYGxPVk6PjJ5Mh?=
SW-684 MlX2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFnHWmt,PSEQvF2= MX7EUXNQ MV7JR|UxRjVwMECg{txO NV;NZXhUOTl7OU[yO|I>
H209 M{PUemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mo\pglUh|ryP NY\jeYVpTE2VTx?= M2ezUmlEPTB;MT6xPVMh|ryP NYe3RWVOOTl7OU[yO|I>
MDA-MB-231T Mn;QS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1;1T542KM7:TR?= NGPmV4tFVVOR NYfpfmp5UUN3ME61MlAxKM7:TR?= NILWOoIyQTl7NkK3Ni=>
HT1080/S NIPpc3NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFzPV2l,PSEQvF2= NUXNU3R3TE2VTx?= MWrJR|UxRTBwNUOxJO69VQ>? MXSxPVk6PjJ5Mh?=
H526 0.044 MmDHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGnOSll,PSEQvF2= MnPHSG1UVw>? NYLYV|VEUUN3ME2wMlA1PCEQvF2= NULsOVRmOTl7OU[yO|I>
DU4475 2.431 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFLrV3h,PSEQvF2= NH\sZo1FVVOR NH6w[ZhKSzVyPUKuOFMyKM7:TR?= M2PYW|E6QTl4Mkey
HCT116 MnrFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2DISJ42KM7:TR?= NYLEXXRwTE2VTx?= MVfJR|UxRTBwOEWyJO69VQ>? Ml74NVk6QTZ{N{K=
M109 M2TUS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoXhglUh|ryP M4\EPGROW09? M2jyTWlEPTB;MT6wOVUh|ryP MUCxPVk6PjJ5Mh?=
BT549 M1jEXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVj+OUDPxE1? NGnQRXVFVVOR MYrJR|UxRTFwNkS1JO69VQ>? NUPsTmRWOTl7OU[yO|I>
HCT116/VM46 NX:5c2FUT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3m2[p42KM7:TR?= MXXEUXNQ NFHRempKSzVyPUGuO|AzKM7:TR?= NWe0XYl{OTl7OU[yO|I>
H460 Mo\PS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVnC[ZhGhjVizszN NXPC[5lnTE2VTx?= M1n2O2lEPTB;MD63PVUh|ryP Ml7tNVk6QTZ{N{K=
MCF-7 M1HJNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnfEglUh|ryP NUjBcnZ7TE2VTx?= MYjJR|UxRTBwMEG2JO69VQ>? MoG3NVk6QTZ{N{K=
GEO MkHkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MojtglUh|ryP MnHHSG1UVw>? MY\JR|UxRTBwM{W2JO69VQ>? NH6yTGIyQTl7NkK3Ni=>
H441 0.646 M1O0[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVP+OUDPxE1? M1vIcmROW09? NULzUZZEUUN3ME2wMlY1PiEQvF2= MV2xPVk6PjJ5Mh?=
MCF-7-807R NVLiXldnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NU\w[ZRKhjVizszN MVfEUXNQ NFTZXYdKSzVyPUCuOFkh|ryP NXPK[WR6OTl7OU[yO|I>
Colo205 Ml7RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NV\zVZk5hjVizszN MmTqSG1UVw>? NILlboJKSzVyPUCuNVA1KM7:TR?= NFv1WVcyQTl7NkK3Ni=>
H292 NIjyTIpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVTCbnV3hjVizszN MofiSG1UVw>? MWfJR|UxRTBwN{i4JO69VQ>? Mn3XNVk6QTZ{N{K=
BT474 (S) NYq1No5FT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkPqglUh|ryP NWrIXHFLTE2VTx?= MUjJR|UxRTJwNECzJO69VQ>? MXOxPVk6PjJ5Mh?=
HT-29 M1XkVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkPrglUh|ryP NUPwVWlYTE2VTx?= NYDLNnhtUUN3ME2yMlExOyEQvF2= NWD0bm5LOTl7OU[yO|I>
A549 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2[yfJ42KM7:TR?= M{DFemROW09? M2DHT2lEPTB;MD62O|Uh|ryP NH7TbpAyQTl7NkK3Ni=>
BT474-M1 M13udGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYPpfHJYhjVizszN MWDEUXNQ Mnq5TWM2OD1{LkO2OUDPxE1? NXmz[5N4OTl7OU[yO|I>
SW480 MmXmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml[5glUh|ryP NUDVXXJsTE2VTx?= MUDJR|UxRjVwMECg{txO NFznTm4yQTl7NkK3Ni=>
L2987 M1TBT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MonGglUh|ryP MXLEUXNQ M4PSfmlEPTB;MD60OFIh|ryP NGKzPWoyQTl7NkK3Ni=>
AU565 NEfxRWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmjaglUh|ryP NGDsVHpFVVOR M360cWlEPTB;ND65O{DPxE1? M1XOTFE6QTl4Mkey
SW403 M2TNWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUf+OUDPxE1? NH7mRZJFVVOR M1fmTmlEPTB;MD6yNkDPxE1? NF3uXoUyQTl7NkK3Ni=>
H1437 Ml7yS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVXWNolphjVizszN NVHqTZl[TE2VTx?= MVTJR|UxRTBwNUKzJO69VQ>? MV2xPVk6PjJ5Mh?=
BT-20 NYnlR45RT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3rLeZ42KM7:TR?= NY\Uc|luTE2VTx?= M1nWeWlEPTB;Mz61OlIh|ryP MUmxPVk6PjJ5Mh?=
Colo320HSR NVTJbGZ7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYD+OUDPxE1? M4\TdmROW09? M1K2ZmlEPTB;MD6wNVEh|ryP NIjCZYcyQTl7NkK3Ni=>
H2087 MnvOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3vsdZ42KM7:TR?= MWPEUXNQ MkHWTWM2OD5zLkCwJO69VQ>? M4rkfFE6QTl4Mkey
HCC1419 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2fEWZ42KM7:TR?= NYfIe2FYTE2VTx?= MV7JR|UxRTJwNUG3JO69VQ>? MljlNVk6QTZ{N{K=
WiDr MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH\NfI9,PSEQvF2= MnXkSG1UVw>? M2GzSWlEPTB;MD6wO|Yh|ryP MXGxPVk6PjJ5Mh?=
H661 0.573 NGHDV|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXHKTHE5hjVizszN NHjSR2tFVVOR NF7ZOIhKSzVyPUCuOVc{KM7:TR?= M{K5XFE6QTl4Mkey
HCC-38 NETDTVhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkPiglUh|ryP NVGwflRmTE2VTx?= NV3scIdKUUN3ME61MlAxKM7:TR?= M17JNlE6QTl4Mkey
LS174T M4\1Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUf+OUDPxE1? M3;nZWROW09? MV7JR|UxRTBwNUO1JO69VQ>? NWDGUoRCOTl7OU[yO|I>
H211 M4T0cGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M33Fep42KM7:TR?= NF;DT2ZFVVOR NE\2bJZKSzVyPUCuO|M{KM7:TR?= MVyxPVk6PjJ5Mh?=
HCC70 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnnUglUh|ryP NGnMVYJFVVOR NWS5TZBPUUN3ME2xMlU2KM7:TR?= NXTHZlV4OTl7OU[yO|I>
SW116 M4XaOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MV\+OUDPxE1? MUjEUXNQ NEPxbmZKSzVyPUCuNFY4KM7:TR?= MV:xPVk6PjJ5Mh?=
H513 NYTKPIQ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX\+OUDPxE1? MlTXSG1UVw>? NYDsOnplUUN3ME20MlQ1QCEQvF2= M2TNWlE6QTl4Mkey
MDA-MB-157 M{jKZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1q1PZ42KM7:TR?= Mo\sSG1UVw>? NUHtXIJQUUN3ME2wMlA{PiEQvF2= MUOxPVk6PjJ5Mh?=
H2052 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEHoXIh,PSEQvF2= NUnOOXdqTE2VTx?= NF3zXHVKSzVyPUGuNFUh|ryP MkSxNVk6QTZ{N{K=
MDA-MB-415 M{fTfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlfNglUh|ryP MU\EUXNQ M1Lue2lEPTB-NT6wNEDPxE1? M{XEeVE6QTl4Mkey
DLD-1 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4rTVJ42KM7:TR?= NEC0dGdFVVOR NFfsNWtKSzVyPUCuPVA6KM7:TR?= Mlz3NVk6QTZ{N{K=
H2595 M1rYbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkjBglUh|ryP M120e2ROW09? NYm3e2hJUUN3ME20MlQ4PSEQvF2= MmDZNVk6QTZ{N{K=
MDA-MB-435S NIDWV4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3u4UJ42KM7:TR?= NF6yeGdFVVOR MmX4TWM2OD1zLki2PUDPxE1? NETmUJgyQTl7NkK3Ni=>
HCT15 M132R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NE\FcYR,PSEQvF2= NWnvUFBTTE2VTx?= M1\UeWlEPTB-MT6wNEDPxE1? NW\IRnlNOTl7OU[yO|I>
SK-Hep1 M3\COmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX3yd|J6hjVizszN NY\DRnlITE2VTx?= MmPPTWM2OD1yLkG0OkDPxE1? NFXEWZgyQTl7NkK3Ni=>
MDA-MB-436 NFLUe|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXL+OUDPxE1? M3zvVWROW09? NYTJUoY1UUN3ME21MlUxOiEQvF2= MnL6NVk6QTZ{N{K=
KM12C NHXBPG5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVnkUYlQhjVizszN NVTHNnVpTE2VTx?= NYTm[nRKUUN3ME2wMlA2PCEQvF2= NWDNUWd1OTl7OU[yO|I>
HEPG2 Ml\SS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWr+OUDPxE1? MX;EUXNQ MWjJR|UxRTBwMEK1JO69VQ>? NXjrc|JuOTl7OU[yO|I>
MDA-MB-453 Moj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEKwV4t,PSEQvF2= NVO1Z212TE2VTx?= NVXjOVR4UUN3ME2xMlg3QSEQvF2= MVqxPVk6PjJ5Mh?=
KM12SM MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYXDOI9EhjVizszN M2nrSmROW09? M4\jTGlEPTB;MD6wOVkh|ryP M3;CRVE6QTl4Mkey
1483 M2XLN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3HRPZ42KM7:TR?= M4L0PWROW09? NH3YbJNKSzVyPUKuNVkh|ryP MnztNVk6QTZ{N{K=
Hs578t NYe5e4x5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYn+OUDPxE1? M13oU2ROW09? NWPIOGRPUUN3ME2xMlI5PyEQvF2= NFW4T4UyQTl7NkK3Ni=>
LS180 NILVRYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmL0glUh|ryP NVqyXYhVTE2VTx?= M2r1dGlEPTB;MD62PVYh|ryP Mmr3NVk6QTZ{N{K=
FaDu NU[4OJltT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1T4Sp42KM7:TR?= NIm4[ZFFVVOR MUPJR|UxRTFwMkeg{txO NYHXfIIxOTl7OU[yO|I>
ZR-75-1 NX3yWWVZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlLvglUh|ryP NHTzNWJFVVOR MkLsTWM2OD1{LkC4OEDPxE1? M3z5OVE6QTl4Mkey
LS513 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX3+OUDPxE1? MYLEUXNQ NFjHTY5KSzVyPUCuNVM2KM7:TR?= NF\NfIQyQTl7NkK3Ni=>
Detroit.562 NVvFXG02T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2i5[p42KM7:TR?= MYjEUXNQ MX\JR|UxRTFwMUSg{txO NIjDSI4yQTl7NkK3Ni=>
ZR-75-30 NVT4Vo5QT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVnadZprhjVizszN NHrHVm5FVVOR M3\JR2lEPTB-NT6wNEDPxE1? M3TlelE6QTl4Mkey
RKO-PM NHHoUo5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEmzRVR,PSEQvF2= NXjRbGhoTE2VTx?= M1:ySmlEPTB;MD6yN|Ih|ryP NWjsb2k5OTl7OU[yO|I>
Cal.27 NXH0[IhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYrIR2NZhjVizszN MmrwSG1UVw>? M1i0bmlEPTB;MjFOwG0> NIfle3EyQTl7NkK3Ni=>
KPL4 M3PuVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MX;+OUDPxE1? MXzEUXNQ MmGxTWM2OD1zLkK1NkDPxE1? NGS0ZlQyQTl7NkK3Ni=>
PKO-RM13 NH7kR3ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX7+OUDPxE1? M1vLb2ROW09? MVPJR|UxRTBwNEK1JO69VQ>? NX3uZ25bOTl7OU[yO|I>
HS.53.T MmS4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIT3R45,PSEQvF2= MkS5SG1UVw>? MX7JR|UxRTBwN{mg{txO MXSxPVk6PjJ5Mh?=
EMT6 M3Hidmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoS2glUh|ryP NFXSTYVFVVOR MnrMTWM2OD1yLkiwOkDPxE1? M{mxRlE6QTl4Mkey
SNU-C1 M{jzR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{njb542KM7:TR?= NXfJc2dpTE2VTx?= MXLJR|UxRTBwMEC3JO69VQ>? MUKxPVk6PjJ5Mh?=
SQCCY1 MmLUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlXqglUh|ryP NGm0eZdFVVOR MULJR|UxRTBwN{mg{txO NUXmWGFLOTl7OU[yO|I>
SW480 MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUT+OUDPxE1? NFPIbZdFVVOR NHrBcINKSzVyPUCuNFM4KM7:TR?= NUfMcJkzOTl7OU[yO|I>
SCC9 MkPwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3;nXJ42KM7:TR?= NGP1NWZFVVOR M3jac2lEPTB;MD63OUDPxE1? NIr1NIIyQTl7NkK3Ni=>
SK-LMS-1 M3PBeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVP+OUDPxE1? NG\PfIpFVVOR NVPYdpZ5UUN3ME2wMlY5PyEQvF2= M4\P[lE6QTl4Mkey
SCC25 NFnkV49Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MUL+OUDPxE1? Mn34SG1UVw>? MonqTWM2OD1yLk[4JO69VQ>? NVjV[I5VOTl7OU[yO|I>
U87 NXm1Z3JkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1KzO542KM7:TR?= NYTscoR7TE2VTx?= MYPJR|UxRTBwOUWg{txO M1vsSlE6QTl4Mkey
SCC15 MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUH+OUDPxE1? NGHCZYdFVVOR NFfFXXpKSzVyPUCuOlch|ryP M3Xvb|E6QTl4Mkey
T98G NVTZe4VUT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{e5Up42KM7:TR?= MkfQSG1UVw>? MYrJR|UxRTFwMkG4JO69VQ>? MUWxPVk6PjJ5Mh?=
SCC4 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXL+OUDPxE1? NVWx[HNyTE2VTx?= NYrlWItIUUN3ME2wMlY{KM7:TR?= NFK4epEyQTl7NkK3Ni=>
U118 Mny4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2Xmcp42KM7:TR?= M4\ncWROW09? NGHMe4lKSzVyPUGuOlE5KM7:TR?= NVO3SWdlOTl7OU[yO|I>
TU167 MlrPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NY\XV4ZNhjVizszN MkXCSG1UVw>? NF60cVlKSzVyPUSuOVIh|ryP NGPCdZkyQTl7NkK3Ni=>
NCI-H727 NYXLTlVrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYX+NVDjiIsQvF2= MV;EUXNQ MXTJR|UxRTR{ODDuUS=> MmLINlA{QDV5NEe=
NCI-H720 MoH2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUT+NVDjiIsQvF2= MX\EUXNQ MofiTWM2OD1{Lkig{txO NHLVS5YzODN6NUe0Oy=>
NCI-H835 NF7XNFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXPUOmVjhjFy4pEK{txO NXPtOVRKTE2VTx?= MnHoTWM2OD1zIN88US=> NGXIVI0zODN6NUe0Oy=>
NCI-H727 M4LG[WtqdmG|ZTDhd5NigQ>? NVr2N|hthjFy4pEK{txO NV\lZlAzTE2VTx?= NFXo[GtqdmirYnn0d{Bkd26|dHn0eZRqfmViSVfGNXIh[XW2b4Doc5NxcG:{eXzheIlwdg>? MX6yNFM5PTd2Nx?=
RD MoXtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYW3VlBqhjFy4pEK{txO MYLJR|UxRTFwMUKgxtVO MYiyNVI6QDd2NR?=
Rh41 MlLYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUXrW|k2hjFy4pEK{txO MnPZTWM2OD1yLkC3JOK2VQ>? MXSyNVI6QDd2NR?=
Rh18 NFnKV2hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkP2glEx6oDMzszN NYDRfIN5UUN3ME20Mlk3KML3TR?= MUGyNVI6QDd2NR?=
Rh30 NV\EPVB1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUfaRY5LhjFy4pEK{txO MWDJR|UxRTBwMUmgxtVO MYKyNVI6QDd2NR?=
BT-12 NES2ZZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmKzglEx6oDMzszN M2HXb2lEPTB;MD63PEDDvU1? MXeyNVI6QDd2NR?=
CHLA-266 MlO1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX7+NVDjiIsQvF2= NIrZeFRKSzVyPUCuPFkhyrWP NWnwfJR3OjF{OUi3OFU>
TC-71 NV74foEyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4PVVZ4yOOLCit88US=> NXLMXVFKUUN3ME2wMlEyKML3TR?= NVm5eoJ[OjF{OUi3OFU>
CHLA-9 MkOwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnfUglEx6oDMzszN NGPOTWJKSzVyPUCuNVIhyrWP NH;aT|gzOTJ7OEe0OS=>
CHLA-10 NH3ESpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH3lS4R,OTEkgJtOwG0> NWLlTXJCUUN3ME2wMlYzKML3TR?= M2rZUVIyOjl6N{S1
CHLA-258 MkfsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHLSS3p,OTEkgJtOwG0> MkfSTWM2OD1yLkK3JOK2VQ>? NIfpUZUzOTJ7OEe0OS=>
GBM2 MnHES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLBblFUhjFy4pEK{txO NWXI[XQzUUN3ME2xMlQ4KML3TR?= MXeyNVI6QDd2NR?=
NB-1643 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{m5bZ4yOOLCit88US=> M{LqPGlEPTB;MD6xNkDDvU1? NFfqZpozOTJ7OEe0OS=>
NB-EBc1 M{\OT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX;GcFhDhjFy4pEK{txO NVi3OlhlUUN3ME2wMlM2KML3TR?= M3\sWFIyOjl6N{S1
CHLA-90 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVOy[oFKhjFy4pEK{txO MnftTWM2OD1yLke3JOK2VQ>? NHHrZ|UzOTJ7OEe0OS=>
CHLA-136 NUjScVlKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVf+NVDjiIsQvF2= MUjJR|UxRTBwNUKgxtVO NIPvV3EzOTJ7OEe0OS=>
NALM-6 NIrjd4ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYH+NVDjiIsQvF2= NU\SUWhPUUN3ME2wMlQ6KML3TR?= Moe0NlEzQTh5NEW=
COG-LL-317 Mlj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH7tbJJ,OTEkgJtOwG0> NF\FRlRKSzVyPUGuN|ghyrWP MWSyNVI6QDd2NR?=
RS4;11 Ml7DS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXz1c|kyhjFy4pEK{txO M{WydGlEPTB;MD6zPEDDvU1? MmP0NlEzQTh5NEW=
MOLT-4 MkLjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUP+NVDjiIsQvF2= NWfXc4x7UUN3ME2wMlU{KML3TR?= M3:zNVIyOjl6N{S1
CCRF-CEM NVj5emZ7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnfJglEx6oDMzszN M4i1XGlEPTB;MT6xN{DDvU1? NHnreHMzOTJ7OEe0OS=>
Kasumi-1 NEXVcXlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHTkTI5,OTEkgJtOwG0> NHPwdWdKSzVyPUGuNkDDvU1? NF\SdZQzOTJ7OEe0OS=>
Karpas-299 NVrCS4w6T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MV7+NVDjiIsQvF2= NHPNb3FKSzVyPUGuOlQhyrWP MkLDNlEzQTh5NEW=
Ramos-RA1 NYP3bYxJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXm3RoEyhjFy4pEK{txO NEDW[phKSzVyPUGuN|EhyrWP Mnv3NlEzQTh5NEW=
Rh30  NW\LWFBKTnWwY4Tpc44h[XO|YYm= MlnLbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w NHSzUJozPTl{NUO3PC=>
Rh41 NYTjSXVWTnWwY4Tpc44h[XO|YYm= MXHpcoR2[2W|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25? NImyWYozPTl{NUO3PC=>
RD MlvVSpVv[3Srb36gZZN{[Xl? M1O2c4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= MVqyOVkzPTN5OB?=
A549 MljZT4lv[XOnIHHzd4F6 M1;s[VAvPeLCit88US=> NY\DUmlPTE2VTx?= M33wcIlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v NEj6b5ozPjl{OEW3PC=>
NCI-H358 NGXCdGlMcW6jc3WgZZN{[Xl? NFXZXFAxNjYkgJtOwG0> M1;YbGROW09? NXfoWGFWcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25? M2SyeFI3QTJ6NUe4
A549 NGPsbJNHfW6ldHnvckBie3OjeR?= M{\mXVAvPeLCit88US=> MVvEUXNQ NWXNdYdr[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?= MnPLNlY6Ojh3N{i=
NCI-H358 NVjY[GliTnWwY4Tpc44h[XO|YYm= MVOwMlXjiIsQvF2= M{T4dmROW09? M1S1cINifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt? NU[xWI93OjZ7Mki1O|g>
A549 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYq1XYk1hjFy4pEK{txO NITjXmJFVVOR NX\Y[pE1UUN3ME2wMlc3KM7:TR?= NV[wUmNzOjZ7Mki1O|g>
NCI-H358 M2TRPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHPrcXd,OTEkgJtOwG0> MYTEUXNQ M{LkdGlEPTB;MT6wPUDPxE1? MkHxNlY6Ojh3N{i=
A549 NIHnXZJCeG:ydH;zbZMh[XO|YYm= Mn\BNE426oDMzszN M1nnV2ROW09? NH\VRVdqdmS3Y3XzJGFxd3C2b4Ppdy=> NYnqOYZIOjZ7Mki1O|g>
NCI-H358 NU\jS2g5SXCxcITvd4l{KGG|c3H5 NES0SWExNjYkgJtOwG0> NFrITodFVVOR NUTFfZdncW6mdXPld{BCeG:ydH;zbZM> M1;MfFI3QTJ6NUe4
A549 NHq1fWhHfW6ldHnvckBie3OjeR?= NGHVTlkxNjYkgJtOwG0> MnPESG1UVw>? M4TQPJJm\HWlZYOge492dmRiY3zvd5Vz\Q>? NIjvVZAzPjl{OEW3PC=>
NCI-H358 NHOyb5FHfW6ldHnvckBie3OjeR?= NUnlZ4ZmOC534pEK{txO NEfzN|VFVVOR NILCO3hz\WS3Y3XzJJdwfW6mIHPsc5N2emV? M1[xXVI3QTJ6NUe4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
体内研究 BMS-754807(12.5mg/kg,口服)作用于携带 IGF-1R-Sal肿瘤的裸鼠,抑制肿瘤和血清中IGF-1R磷酸化。BMS-754807作用于一组选定的上皮(IGF-1R-Sal, GEO, 和Colo205),造血(JJN3)和间质(RD1和Rh41)移植瘤模型,抑制肿瘤生长,肿瘤生长抑制率从53%至115%不等。[1] BMS-754807 (6.25 mg/kg) 作用于转基因的IGF-Sal肿瘤小鼠模型,完全抑制肿瘤生长,且抑制pIGF-1R 和 pAKT。BMS-754807与小鼠血浆和人类血浆的蛋白结合率分别为98.5% 和95.9%。BMS-754807 (25 mg/kg)作用于携带KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), 和 OS-1移植瘤的小鼠模型,显著抑制肿瘤。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶抑制实验:

在体外激酶实验中使用重组人类 IGF-1受体酶测定BMS-754807,在生化实验中使用合成肽KKSRGDYMTMQIG 作为磷酸受体底物测定BMS-754807。在Ubottom 384孔板中使用 30 μL实验缓冲液 (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT)来进行酶活测定。通过结合ATP,1.5 μM 荧光标记肽底物, 酶和BMS-754807而开始反应,反应持续60分钟。加入EDTA终止反应。通过电泳分离荧光底物和磷酸化产物,然后在Caliper LabChip 3000上分析反应混合物。通过对剂量反应曲线进行非线性回归分析而获得IC50值。
细胞实验:[1]
- 合并
  • Cell lines: IGF-1R-Sal, RH41 和 Geo 细胞系
  • Concentrations: 365 nM
  • Incubation Time: 72 小时
  • Method: 细胞按最佳密度培养在RPMI + GLUTAMAX培养基中,培养基中含有有10% 热灭活的胎牛血清(FBS),10mMHepes,青霉素和链霉素。BMS-754807处理细胞72小时后,通过测定3H-胸甘渗透到DNA中的程度而测评细胞增殖。结果表示为IC50。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带IGF-1R-Sal, GEO, Colo205, JJN3, RD1 或 Rh41 肿瘤的裸鼠
  • Dosages: 150 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 461.49
化学式

C23H24FN9O

CAS号 1001350-96-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买BMS-754807 | BMS-754807供应商 | 采购BMS-754807 | BMS-754807价格 | BMS-754807生产 | 订购BMS-754807 | BMS-754807代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID